header image

Stockholm, Sweden

History:

 

Located at Lake Mälaren in the west of Stockholm, Sweden, and originally owned by Kabi (later Pharmacia, and then spin-off Biovitrum), the site has been involved in plasma fractionation since the 1940s. The first plasma protein, albumin, was supplied to the market in 1949 followed by gamma globulin in 1950. In the mid-1960s, Kabi was one of the first commercial companies in the world to introduce a Factor VIII concentrate.

 

Octapharma acquired the facility, which was at that time the Plasma Products Division of Biovitrum, in July 2002. The production facilities were subsequently converted to enable the continuous production of both Biovitrum’s existing plasma products as well as Octapharma’s product range. Ongoing investments of more than $165 million into the acquisition and adaptation of expanded premises, such as the historic brewery building, as well as installation of state-of-the-art production equipment, have increased the facility’s annual capacity seven-fold from 2002–2012. Today, there are 600 employees in Stockholm.

 

In 2003, the pharmaceutical development of Octapharma's recombinant Factor VIII was transferred from basic research at Octapharma Biopharmaceuticals GmbH, Munich, to the Stockholm development and pilot facility.

 

The facility’s Quality System, which already held an FDA license, has been harmonised with the Octapharma system, making the Stockholm facility a valuable contributor in supplying the US market.

 

On-site units:

 

Fractionation/purification; pharmaceutical production; labeling, packaging and storage facilities; Quality Control laboratories; PCR testing; pilot facility and full-scale production facility for recombinant factor VIII; administrative units.

 

On-site subsidiaries:

 

Octapharma OAB (Operations)

Octapharma Nordic (Marketing & Sales)